Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression

References

• Comiskey MC, Dallos MC, Drake CG. Immunotherapy in prostate cancer: teaching an old dog new tricks. Curr Oncol Rep. 2018;20:75. doi: 10.1007/s11912-018-0712-z.
   PubMed Web of Science ®Google Scholar
• Bilusic M, Madan RA, Gulley JL. Immunotherapy of prostate cancer: facts and hopes. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:6764–11. doi:10.1158/1078-0432.CCR-17-0019.
   PubMed Web of Science ®Google Scholar
• Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, et al. Tn-MUC1 DC vaccination of rhesus macaques and a phase I/II trial in patients with nonmetastatic castrate-resistant prostate cancer. Cancer Immunol Res. 2016;4:881–892. doi:10.1158/2326-6066.CIR-15-0189.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069–1086. doi:10.1158/2159-8290.CD-18-0367.
   PubMed Web of Science ®Google Scholar
• Dempke WCM, Fenchel K, Uciechowski P, Dale SP. Second- and third-generation drugs for immuno-oncology treatment-The more the better? Eur J Cancer Oxf Engl 1990. 2017;74:55–72. doi: 10.1016/j.ejca.2017.01.001.
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol J Hematol Oncol. 2018;11:39. doi:10.1186/s13045-018-0582-8.
   PubMed Web of Science ®Google Scholar
• Longo V, Brunetti O, Azzariti A, Galetta D, Nardulli P, Leonetti F, Silvestris N. Strategies to improve cancer immune checkpoint inhibitors efficacy, other than abscopal effect: a systematic review. Cancers. 2019;11(4):539. doi:10.3390/cancers11040539.
   PubMed Web of Science ®Google Scholar
• Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700–712. doi:10.1016/S1470-2045(14)70189-5.
   PubMed Web of Science ®Google Scholar
• Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2017;Jan;35(1):40–47. doi:10.1200/JCO.2016.69.1584.
   Google Scholar
• Jafari S, Molavi O, Kahroba H, Hejazi MS, Maleki-Dizaji N, Barghi S, Kiaie SH, Jadidi-Niaragh F. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer. Cell Mol Life Sci CMLS. 2020 Oct;77(19):3693-3710. doi: 10.1007/s00018-020-03459-1.
   Web of Science ®Google Scholar
• Markowski MC, Shenderov E, Eisenberger MA, Kachhap S, Pardoll DM, Denmeade SR, Antonarakis ES. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. The Prostate. 2020;80(5):407–411. doi:10.1002/pros.23955.
   PubMed Web of Science ®Google Scholar
• Isaacsson Velho P, Antonarakis ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol. 2018;11:475–486. doi:10.1080/17512433.2018.1464388.
   PubMed Web of Science ®Google Scholar
• Hudson LE, Allen RL. Leukocyte Ig-like receptors - a model for MHC class i disease associations. Front Immunol. 2016;7:281. doi: 10.3389/fimmu.2016.00281.
   PubMed Web of Science ®Google Scholar
• Naji A, Menier C, Maki G, Carosella ED, Rouas-Freiss N. Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction. Leukemia. 2012;26:1889–1892. doi:10.1038/leu.2012.62.
   PubMed Web of Science ®Google Scholar
• Brown D, Trowsdale J, Allen R. The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens. 2004;64:215–225. doi: 10.1111/j.0001-2815.2004.00290.x.
   PubMed Web of Science ®Google Scholar
• Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Andry C, Annala M, Aprikian A, Armenia J, Arora A, et al. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–1025. doi:10.1016/j.cell.2015.10.025.
   PubMed Web of Science ®Google Scholar
• Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2018;19:76–84. doi:10.1038/s41590-017-0004-z.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhong S, Niu X, Jiang J, Zhang R, Li Q. The MHC class I-LILRB1 signalling axis as a promising target in cancer therapy. Scand J Immunol. 2019;90:e12804. doi:10.1111/sji.12804.
   PubMed Web of Science ®Google Scholar
• Long Q, Xu J, Osunkoya AO, Sannigrahi S, Johnson BA, Zhou W, Gillespie T, Park JY, Nam RK, Sugar L, et al. Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. Cancer Res. 2014;74(12):3228–3237. doi:10.1158/0008-5472.CAN-13-2699.
   PubMed Web of Science ®Google Scholar
• Wyatt AW, Mo F, Wang K, McConeghy B, Brahmbhatt S, Jong L, Mitchell DM, Johnston RL, Haegert A, Li E, et al. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol. 2014;15(8):426. doi:10.1186/s13059-014-0426-y.
   PubMed Web of Science ®Google Scholar
• Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, et al. Widespread and functional RNA circularization in localized prostate cancer. Cell. 2019;176(4):831–843.e22. doi:10.1016/j.cell.2019.01.025.
   PubMed Web of Science ®Google Scholar
• Bryant G, Wang L, Mulholland DJ. Overcoming oncogenic mediated tumor immunity in prostate cancer. Int J Mol Sci. 2017;18(7):1542. doi:10.3390/ijms18071542.
   PubMed Web of Science ®Google Scholar
• Rohart F, Gautier B, Singh A, Cao K-A, Schneidman D. L. mixOmics: an R package for ‘omics feature selection and multiple data integration. PLOS Comput Biol. 2017;13:e1005752. doi:10.1371/journal.pcbi.1005752.
   PubMed Web of Science ®Google Scholar
• Ivarsson MA, Michaëlsson J, Fauriat C. Activating killer cell Ig-like receptors in health and disease. Front Immunol. 2014;5:184. doi: 10.3389/fimmu.2014.00184.
   PubMed Web of Science ®Google Scholar
• Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000;60:5857–5861.
   PubMed Web of Science ®Google Scholar
• Erlandsson A, Carlsson J, Lundholm M, Fält A, Andersson S-O, Andrén O, Davidsson S. M2 macrophages and regulatory T cells in lethal prostate cancer. The Prostate. 2019;79(4):363–369. doi:10.1002/pros.23742.
   PubMed Web of Science ®Google Scholar
• Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F, Systematic A. Review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68:267–279. doi:10.1016/j.eururo.2015.02.032.
   PubMed Web of Science ®Google Scholar
• Hayat SMG, Bianconi V, Pirro M, Jaafari MR, Hatamipour M, Sahebkar A. CD47: role in the immune system and application to cancer therapy. Cell Oncol Dordr. 2019;43:19-30. doi:10.1007/s13402-019-00469-5.
   Web of Science ®Google Scholar
• Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O’Rourke T, Narayanan S, Papadopoulos K, et al. First-in-human, first-in-class phase i trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:946–953. doi:10.1200/JCO.18.02018.
   PubMed Web of Science ®Google Scholar
• Andrews S. 2010. FastQC: a quality control tool for high throughput sequence data. Available online at:http://www.bioinformatics.babraham.ac.uk/projects/fastqc
   Google Scholar
• Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–2120. doi:10.1093/bioinformatics/btu170.
   PubMed Web of Science ®Google Scholar
• Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34:525–527. doi:10.1038/nbt.3519.
   PubMed Web of Science ®Google Scholar
• Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Research. 2015;4:1521. doi:10.12688/f1000research.7563.1.
   PubMedGoogle Scholar
• Smedley D, Haider S, Durinck S, Pandini L, Provero P, Allen J, Arnaiz O, Awedh MH, Baldock R, Barbiera G, et al. The BioMart community portal: an innovative alternative to large, centralized data repositories. Nucleic Acids Res. 2015;43(W1):W589–W598. doi:10.1093/nar/gkv350.
   PubMed Web of Science ®Google Scholar
• Kinsella RJ, Kähäri A, Haider S, Zamora J, Proctor G, Spudich G, Almeida-King J, Staines D, Derwent P, Kerhornou A, et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database (Oxford). 2011 Jul 23;2011:bar030. doi: 10.1093/database/bar030.
   Google Scholar
• Risso D, Ngai J, Speed TP, Dudoit S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat Biotechnol. 2014;32:896–902. doi:10.1038/nbt.2931.
   PubMed Web of Science ®Google Scholar
• Gagnon-Bartsch JA, Speed TP. Using control genes to correct for unwanted variation in microarray data. Biostatistics. 2012;13:539–552. doi:10.1093/biostatistics/kxr034.
   PubMed Web of Science ®Google Scholar
• Vajda A, Marignol L, Barrett C, Madden SF, Lynch TH, Hollywood D, Perry AS. Gene expression analysis in prostate cancer: the importance of the endogenous control. The Prostate. 2013;73:382–390. doi:10.1002/pros.22578.
   PubMed Web of Science ®Google Scholar
• Chua SL, See Too WC, Khoo BY, Few LL. UBC and YWHAZ as suitable reference genes for accurate normalisation of gene expression using MCF7, HCT116 and HepG2 cell lines. Cytotechnology. 2011;63:645–654. doi:10.1007/s10616-011-9383-4.
   PubMed Web of Science ®Google Scholar
• de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest. 2005;85:154–159. doi:10.1038/labinvest.3700208.
   PubMed Web of Science ®Google Scholar
• Ohl F, Jung M, Xu C, Stephan C, Rabien A, Burkhardt M, Nitsche A, Kristiansen G, Loening SA, Radonić A, et al. Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med. 2005;83:1014–1024. doi:10.1007/s00109-005-0703-z.
   PubMed Web of Science ®Google Scholar
• Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015;12: 697–697. doi:10.1038/nmeth.3485.
   PubMed Web of Science ®Google Scholar
• Seshan VE, Olshen A DNAcopy: DNA copy number data analysis. (Bioconductor version: Release (3.10), 2020). doi:10.18129/B9.bioc.DNAcopy.
   Google Scholar
• Yu G, Wang L-G, He Q-Y. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics. 2015;31:2382–2383. doi:10.1093/bioinformatics/btv145.
   PubMed Web of Science ®Google Scholar
• Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, Handsaker RE, Lunter G, Marth GT, Sherry ST, et al. The variant call format and VCFtools. Bioinformatics. 2011;27:2156–2158. doi:10.1093/bioinformatics/btr330.
   PubMed Web of Science ®Google Scholar
• Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik B, Galon J, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16(1). doi:10.1186/s13059-015-0620-6.
   PubMedGoogle Scholar
• Rohart F, Eslami A, Matigian N, Bougeard S, Lê Cao K-A. MINT: a multivariate integrative method to identify reproducible molecular signatures across independent experiments and platforms. BMC Bioinform. 2017;18:128. doi: 10.1186/s12859-017-1553-8.
   Web of Science ®Google Scholar
• Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, Denkert C. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7(12):e51862. doi:10.1371/journal.pone.0051862.
   PubMed Web of Science ®Google Scholar